The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
about
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisCIViC databaseSunitinib: the antiangiogenic effects and beyondSunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectivesClinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial BioparametersWhat are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and managementClinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours.microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis.Vinblastine-induced apoptosis of melanoma cells is mediated by Ras homologous A protein (Rho A) via mitochondrial and non-mitochondrial-dependent mechanisms.An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation.Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis.Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors.Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review
P2860
Q26800005-C7A8CF58-D80F-4581-92C6-4DDE411AD619Q27612411-CC41F22C-DF74-496F-9F5A-DFED8380B8A0Q28066499-7928FEB9-3384-4634-8417-61EFFBAB63AEQ28069560-94C1B487-2894-4C4C-9901-F1F04CFAD20DQ33633431-A0CEB852-8173-42B5-99CB-E3A97888F7B7Q33814571-96DA3EC2-9556-4039-9F82-3AFA7E735513Q34403301-AE2ADC98-AF8C-422A-A745-A1AF61D74D49Q34468729-FE643B96-FD3C-46C6-852E-CC66BB56D0F9Q34662946-E0F3BE80-8481-4377-B98D-9F10E2F73162Q35895558-105F9378-E225-4920-9BCB-3A35013C21BDQ35921573-FA2A9F1A-BBB5-4840-BB4C-BEBB3D789DAEQ36125976-D1988A8D-370E-46E3-A513-AFF9E008A409Q36697575-221BF209-BF4D-4DD2-BD7F-5B3D4DEE1A15Q37291272-446B2EF8-D395-442D-BC1F-CE57294D4CDCQ37342226-68900A13-5062-4026-8440-5E4CDF25590BQ37519042-C333BF9E-9E3B-4B8B-B13A-4BA5DFE6C998Q38112821-8AA68F6B-A763-4433-86A7-E4DA68E7C960Q38307997-3031B706-E626-4E65-8FBE-80BBC01C665CQ38826494-403366B1-4486-4D47-BE70-C4C6D66D17B6Q38883917-7B1B8F84-6485-40F6-AF8A-8D4B4187A26AQ39007220-9979DE53-01C9-402E-B60A-74DE27D8F113Q39068344-803ECB93-A989-484D-ABF5-EAB818EF1303Q39169845-B445BB96-20BC-424C-BD7C-E94C96C6C3BBQ40452107-532AEC24-7858-42C0-9595-58401374EF5BQ43243489-916FC5DE-560E-4B3B-B90F-6DAD9D5E6E7BQ44001600-A33B0442-9DE8-4C08-90BA-6DD7B205B607Q46783356-40E0AA3D-3798-401C-960C-AF46570C37D7Q47114063-358EC8A0-5468-474F-AAB7-A77EEAD0F78AQ53142244-DB98BC33-2D13-4B23-BE3F-B6AAEC04436EQ53335025-B6E9B58A-C245-4284-8009-B11311572860Q58702198-6AC790E8-CDFC-4B1E-8671-A24F51BC5301
P2860
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The outcome and predictive fac ...... ilure - one institution study.
@ast
The outcome and predictive fac ...... ilure - one institution study.
@en
The outcome and predictive fac ...... ilure - one institution study.
@nl
type
label
The outcome and predictive fac ...... ilure - one institution study.
@ast
The outcome and predictive fac ...... ilure - one institution study.
@en
The outcome and predictive fac ...... ilure - one institution study.
@nl
altLabel
The outcome and predictive fac ...... ailure - one institution study
@en
prefLabel
The outcome and predictive fac ...... ilure - one institution study.
@ast
The outcome and predictive fac ...... ilure - one institution study.
@en
The outcome and predictive fac ...... ilure - one institution study.
@nl
P2093
P2860
P3181
P356
P1433
P1476
The outcome and predictive fac ...... ilure - one institution study.
@en
P2093
Agnieszka Woźniak
Anna Klimczak
Czesław Osuch
Elżbieta Bylina
Ewa Mierzejewska
Iwona Lugowska
Jacek Kroc
Janusz A Siedlecki
Kacper Wasielewski
Magdalena Brzeskwiniewicz
P2860
P2888
P3181
P356
10.1186/1471-2407-12-107
P407
P577
2012-03-22T00:00:00Z
P5875
P6179
1002590166